Mergers & Acquisitions ·
Indivior Pharmaceuticals reported second quarter 2026 financial results on August 3, 2026, announcing total net…
INDVSupernus, Inc.
Indivior Pharmaceuticals reported second quarter 2026 financial results on August 3, 2026, announcing total net revenue of $343 million, a 14% increase year-over-year. Total SUBLOCADE net revenue reached a record $253 million, up 21%, driven by an 18% growth in U.S. dispense unit volume and new patient starts totaling 32,816. The company reported GAAP net income of $122 million ($0.98 diluted EPS) and Adjusted EBITDA of $186 million, representing a 111% increase from the prior year period. Management raised full-year 2026 guidance, projecting total net revenue between $1,295 million and $1,365 million and adjusted EBITDA between $700 million and $740 million. Additionally, Indivior announced a definitive all-stock merger agreement with Supernus Pharmaceuticals to create a diversified CNS-focused biopharmaceutical company, expected to close in the fourth quarter of 2026. The company repurchased approximately 4.7 million shares for $175 million during the quarter. Indivior operates in the pharmaceutical industry, specializing in long-acting injectable treatments for opioid use disorder.